润都股份：厄贝沙坦片增加75mg规格获批

Core Viewpoint - The company, Rundu Co., Ltd. (002923), has received approval from the National Medical Products Administration for a supplementary application regarding the drug Irbesartan, which includes the addition of a new 75mg specification and the issuance of a drug approval number [1] Group 1 - The approved supplementary application allows for the new specification of Irbesartan tablets to be packaged in high-density polyethylene bottles for oral solid medication [1] - The changes include updated quality standards and production processes, which will be effective for 18 months [1] - The product's instructions and packaging labels will be revised accordingly, while other aspects will follow the original approved content [1]